Kliniska studier vid Tema Cancer

TRIM. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow up after radical surgery of stage IIb-c and III cutaneous malignant Melanoma.

Hildur Helgadottir

Studie immunologisk aktivitet hos melanomtumörer. Studier av immunologisk aktivitet hos melanomtumörer som opereras bort

Hildur Helgadottir

PROMMEL. Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

Hildur Helgadottir

Bio-Melanom. En provsamlingsstudie för att identifiera biomarkörer av betydelse för behandlingseffekt och toxicitet vid medicinsk behandling av patienter med malignt melanom

Fernanda Costas Svedman

Melbank-studien. Studier på primära melanom och högrisk sjukdom.

Hanna Eriksson

PRISM-MEL-301. A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Hanna Eriksson

SCANDIUM III. A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial

Hildur Helgadottir

GRAND-SLAM. A prospective randomized international multicenter study to compare Short versus Long Adjuvant immunotherapy after radical surgery of stage IIb-c, III and IV cutaneous malignant Melanoma

Hildur Helgadottir

Immu-LC-studien. Det immunologiska landskapet- lungcancer, The immunological landscape in lung cancer. Studies of effector mechanisms and biomarkers in patients with NCLC undergoing treatment with checkpoint inhibitors

Luigi De Petris

PreDDLung-studien tid Biobank-Lung. Uppbyggnad av biobank för lungcancerforskning vid Karolinska Universitetssjukhuset

Simon Ekman

MO41552-ROS 1. A randomised, open label, multicentre, phase 3 study of entrectinib versus crizotinib in patients with locally-advanced or metastatic non-small cell lung cancer harbouring ROS1 gene rearrangements with and without central nervous system metastases

Georgios Tsakonas

ASAB. ASAB - Alectinib followed by concomitant consolidation SBRT/hypofractionated radiation therapy in advanced NSCLC with ALK-rearrangement

Karin Lindberg

M18-868-Teliso. Phase 3, open-label, randomized, controlled, global study in subjects with c-Met overexpressing (c- Met+), EGFR wildtype, locally advanced/metastatic non-squamous NSCLC that has progressed after standard of care therapy.

Georgios Tsakonas

SOLUCOM. Sotorasib in advanced KRASG12C -mutated non-small cell lung cancer patients with comorbidities (SOLUCOM)

Simon Ekman

PROTHYM. Phase II non-randomized study on Proton Radiotherapy Of Thymic Malignancies

Karin Lindberg

LUCA-S. Web-based symptom monitoring and survival in advanced stage lung cancer

Gunnar Wagenius

BO42777 HORIZON01. A phase 1-3, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according tobiomarker status, with locally advanced, unresectable, stage IIInon-small cell lung cancer

Georgios Tsakonas

TRIPLEX. Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy(TRT) to durvalumab immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

Luigi De Petris

EFS-Frailty in lung cancer. Frailty among elderly patients with advanced lung cancer

Jeanette Winterling

KSAB. Sotorasib followed by SBRT to 1-3 lesions in advanced NSCLC with KRASG12C mutation

Karin Lindberg

ANDROMEDA. Addition of hypofractionated high dose radiation in oligometastatic disease - An open label randomized phase III trial comparing up-front radiation in oligometastatic non-small cell lung cancer (NSCLC) and systemic treatment with systemic treatment alone

Karin Lindberg

ERIS. EGFR-mutated lung cancer in randomized investigator initiated study. ERIS is a national, randomized phase III trial for advanced NSCLC harboring targetable EGFRmutations.The trial is academic and initiated by Swedish Lung Cancer Study Group (SLUSG).Patients will be randomized to third generation EGFR-inhibitor ( osimertinib) or second-generationEGFR-inhibitor (investigator's choice between afatinib and dacomitinib). Primary endpoint is PFS. Series of exploratory molecular analyses are planned on repeatedl

Simon Ekman

Bridge D9106C00002. A multicentre, Phase II, single-arm, interventional study ofneoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, inparticipants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Karin Lindberg

MARS. Multicentre phase III study: Addition of Radiotherapy to Standard chemotherapy for stage IV NSCLC

Signe Friesland

BEAMION-Lung2 . A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic - non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

Simon Ekman

MK-2870-009_Lunga. A Randomized Phase 3 Study of MK-2870 plus Platinum vs. MK-2870 vs. Platinum Doublets in EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Simon Ekman

Galaxies Lung-301 (GSK4428859A). A Randomized, Multi-Center, Double-blind, Placebo Controlled, Phase 3 Study to Investigate Safety and Efficacy of GSK4428859A in combination with Dostarlimab compared with Placebo in combination with Pembrolizumab in Participants with Previously Untreated Locally Advanced, Unresectable or Metastatic PD-L1 Selected Non-Small Cell Lung Cancer (NSCLC)

Hannah Björn Andtback

Artscan IV. A nonrandomized multicenter observational study of all reirradiation in patients with head and neck cancer with special focus on patients receiving proton therapy

Michael Gubanski

ARTSCAN V. ARTSCAN V; Photon therapy versus proton therapy in early tonsil cancer

Michael Gubanski

Predict-HPV-HNC. Studier på markörer för bättre prognosbedömning, uppföljning och behandling av humant papillomvirus positiv huvudhalscancer

Mark Zupancic

JADE/219885. A randomized, double-blind, placebo-controlled phase 3 study to evaluate Dostarlimab as sequential therapy after chemoradiation in participants with locally advanced unresected Head and Neck squamous cell carcinoma

Hanna Carstens

PRO-GLIO. PROton versus photon therapy in IDH-mutated diffuse grade 2 and 3 GLIOmas

Mark Zupancic

HH-Prog-Markör-studien. Prognostiska markörer för bättre uppföljning av huvud-halscancer (som opereras)

Mathias von Beckerath